WHAT IS CLAIMED IS:

1. Use of an antibody-drug conjugate (ADC) that comprises a first antibody that binds a tumor-associated antigen and a cytotoxic agent, wherein the cytotoxic agent is a tubulin disrupter, in the manufacture of a first medicament; and use of a second antibody that binds to an immune cell engager, wherein the second antibody comprises an Fc with enhanced binding to one or more activating FcγRs, wherein the activating FcγRs include one or more of FcγRIIIa, FcγRIIa, and/or FcγRI, in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat cancer.

2. The use of claim 1, wherein the second antibody comprises an Fc with enhanced binding to at least FcγRIIIa, or
wherein second antibody comprises an Fc with enhanced binding to at least FcγRIIIa and FcγRIIa, or
wherein the second antibody comprises an Fc with enhanced binding to at least FcγRIIIa and FcγRI, or
wherein the second antibody comprises an Fc with enhanced binding to FcγRIIIa, FcγRIIa, and FcγRI.

3. The use of claim 1 or 2, wherein the Fc of the second antibody has reduced binding to one or more inhibitory FcγRs, or
wherein the Fc of the second antibody has reduced binding to FcγRIIb.

4. The use of any one of claims 1-3, wherein the Fc of the second antibody has reduced fucose levels and/or has been engineered to comprise one or more mutations such that the Fc has enhanced binding to the one or more activating FcγRs, or
wherein the second antibody is nonfucosylated, or
wherein the second antibody comprises substitutions S293D, A330L, and I332E in the heavy chain constant region.

5. Use of an antibody-drug conjugate (ADC), wherein the antibody-drug conjugate comprises a first antibody conjugated to a cytotoxic agent, wherein the cytotoxic agent is a tubulin disrupter, in the manufacture of a first medicament; and use of a second antibody that

binds an immune cell engager, wherein the second antibody is nonfucosylated, in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat cancer.

6. The use of any one of claims 1-5, wherein the first antibody binds a tumor-associated antigen.

7. Use of an antibody-drug conjugate (ADC), wherein the ADC comprises a first antibody that binds a tumor-associated antigen and a cytotoxic agent, wherein the cytotoxic agent is a tubulin disrupter, in the manufacture of a first medicament; and use of a second antibody that binds an immune cell engager, wherein the second antibody comprises an Fc with enhanced ADCC activity relative to a corresponding wild-type Fc of the same isotype, in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat cancer.

8. The use of claim 7, wherein the second antibody comprises an Fc with enhanced ADCC and ADCP activity relative to a corresponding wild-type Fc of the same isotype.

9. The use of claim 7 or 8, wherein the second antibody is nonfucosylated.

10. The use of any one of claims 7-9, wherein the second antibody comprises an Fc with enhanced binding to one or more activating FcγRs, wherein the activating FcγRs include one or more of FcγRIIIa, FcγRIIa, and/or FcγRI.

11. The use of claim 10, wherein the second antibody comprises an Fc with enhanced binding to at least FcγRIIIa, or
wherein the second antibody comprises an Fc with enhanced binding to at least FcγRIIIa and FcγRIIa, or
wherein the second antibody comprises an Fc with enhanced binding to at least FcγRIIIa and FcγRI, or
wherein the second antibody comprises an Fc with enhanced binding to FcγRIIIa, FcγRIIa, and FcγRI.

12. The use of any one of claims 7-11, wherein the Fc of the second antibody has reduced binding to one or more inhibitory FcγRs, or
wherein the Fc of the second antibody has reduced binding to FcγRIIb.

13. The use of any one of claims 1-12, wherein the first antibody binds an antigen selected from 5T4 (TPBG), ADAM-9 , AG-7, ALK, ALP, AMHRII, APLP2, ASCT2, AVB6, AXL (UFO), B7-H3 (CD276), B7-H4, BCMA, C3a, C3b, C4.4a (LYPD3), C5, C5a, CA6, CA9, CanAg, carbonic anhydrase IX (CAIX), Cathepsin D, CCR7, CD1, CD10, CD100, CD101, CD102, CD103, CD104, CD105, CD106, CD107a, CD107b, CD108, CD109, CD111, CD112, CD113, CD116, CD117, CD118, CD119, CD11A, CD11b, CD11c, CD120a, CD121a, CD121b, CD122, CD123, CD124, CD125, CD126, CD127, CD13, CD130, CD131, CD132, CD133, CD135, CD136, CD137, CD138, CD14, CD140a, CD140b, CD141, CD142, CD143, CD144, CD146, CD147, CD148, CD15, CD150, CD151, CD154, CD155, CD156a, CD156b, CD156c, CD157, CD158b2, CD158e, CD158f1, CD158h, CD158i, CD159a, CD16, CD160, CD161, CD162, CD163, CD164, CD166, CD167b, CD169, CD16a, CD16b, CD170, CD171, CD172a, CD172b, CD172g, CD18, CD180, CD181, CD183, CD184, CD185, CD19, CD194, CD197, CD1a, CD1b, CD1c, CD1d, CD2, CD20, CD200, CD201, CD202b, CD203c, CD204, CD205, CD206, CD208, CD21, CD213a1, CD213a2, CD217, CD218a, CD22, CD220, CD221, CD222, CD224, CD226, CD228, CD229, CD23, CD230, CD232, CD239, CD243, CD244, CD248, CD249, CD25, CD26, CD265, CD267, CD269, CD27, CD272, CD273, CD274, CD275, CD279, CD28, CD280, CD281, CD282, CD283, CD284, CD289, CD29, CD294, CD295, CD298, CD3, CD3 epsilon, CD30, CD300f, CD302, CD304, CD305, CD307, CD31, CD312, CD315, CD316, CD317, CD318, CD319, CD32, CD321, CD322, CD324, CD325, CD326, CD327, CD328, CD32b, CD33, CD331, CD332, CD333, CD334, CD337, CD339, CD34, CD340, CD344, CD35, CD352, CD36, CD37, CD38, CD39, CD3d, CD3g, CD4, CD41, CD42d, CD44, CD44v6, CD45, CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD5, CD50, CD51, CD51 (integrin alpha-V), CD52, CD53, CD54, CD55, CD56, CD58, CD59, CD6, CD61, CD62L, CD62P, CD63, CD64, CD66a-e, CD67, CD68, CD69, CD7, CD70, CD70L, CD71, CD71 (TfR), CD72, CD73, CD74, CD79a, CD79b, CD8, CD80, CD82, CD83, CD84, CD85f, CD85i, CD85j, CD86, CD87, CD89, CD90, CD91, CD92, CD95, CD96, CD97, CD98, CDH6, CDH6 (cadherin 6), CDw210a, CDw210b, CEA, CEACAM5, CEACAM6, CFC1B, cKIT, CLDN18.2 (claudin 18.2), CLDN6, CLDN9, CLL-1, c-MET, complement factors C3, Cripto,

CSP-1, CXCR5, DCLK1, DLK-1, DLL3, DPEP3, DR5 (Death receptor 5), Dysadherin, EFNA4 , EGFR, EGFR wild type, EGFRviii, EGP-1 (TROP-2), EGP-2, EMP2, ENPP3, EpCAM, EphA2, EphA3, Ephrin-A4 (EFNA4), ETBR, FAP, FcRH5, FGFR2, FGFR3, FLT3, FOLR, FOLR1, FOLR-alpha, FSH, GCC, GD2, GD3, globo H, GPC1, GPC-1, GPC3, GPNMB, GPR20, HER2, HER-2, HER3, HER-3, HGFR (c-Met), HLA-DR, HM1.24, HSP90, Ia, IGF-1R, IL-13R, IL-15, IL1RAP, IL-2, IL-3, IL-4, IL7R, integrin alphaVbeta3 (integrin αVβ3), integrin beta-6, Interleukin-4 Receptor (IL4R), KAAG-1, KLK2, LAMP-1, Le(y), Lewis Y antigen, LGALS3BP, LGR5, LH/hCG, LHRH, Lipid raft, LIV-1 (SLC39A6 or ZIP6), LRP-1, LRRC15, LY6E, Macrophage mannose receptor 1, MAGE, Mesothelin (MSLN), MET, MHC class I chain-related protein A and B (MICA and MICB), MN/CA IX, MRC2, MT1-MMP, MTX3, MTX5, MUC1, MUC16, MUC2, MUC3, MUC4, MUC5, MUC5ac, NaPi2b, NCA-90, NCA-95, Nectin-4, Notch3, Nucleolin, OAcGD2, OT-MUC1 (onco-tethered-MUC1), OX001L, P1GF, PAM4 antigen, p-cadherin (cadherin 3), PD-L1, Phosphatidyl Serine(PS), PRLR, Prolactin Receptor (PRLR), Pseudomonas, PSMA, PTK4, PTK7, Receptor tyrosine kinase (RTK), RNF43, ROR1, ROR2, SAIL, SEZ6, SLAMF7, SLC44A4, SLITRK6, SLMAMF7 (CS1), SLTRK6, Sortilin (SORT1), SSEA-4, SSTR2, Staphylococcus aureus (antibiotic agent), STEAP-1, STING, STn, T101, TAA, TAC, TDGF1, tenascin, TENB2, TGF-B, Thomson-Friedenreich antigens, Thy1.1, TIM-1, tissue factor (TF; CD142), TM4SF1, Tn antigen, TNF-alpha (TNFα), TRA-1-60, TRAIL receptor (R1 and R2), TROP-2, Tumor-associated glycoprotein 72 (TAG-72), uPAR, VEGFR, VEGFR-2, and xCT, or

wherein the first antibody binds an antigen selected from CD71, Axl, AMHRII, and LGR5, Axl, CA9, CD142, CD20, CD22, CD228, CD248, CD30, CD33, CD37, CD48, CD7, CD71, CD79b, CLDN18.2, CLDN6, c-MET, EGFR, EphA2, ETBR, FCRH5, GCC, Globo H, gpNMB, HER-2, IL7R, Integrin beta-6, KAAG-1, LGR5, LIV-1, LRRC15, Ly6E, Mesothelin (MSLN), MET, MRC2, MUC16, NaPi2b, Nectin-4, OT-MUC1 (onco-tethered-MUC1), PSMA, ROR1, SLAMF7, SLC44A4, SLITRK6, STEAP-1, STn, TIM-1, TRA-1-60, and Tumor-associated glycoprotein 72 (TAG-72), or

wherein the first antibody binds an antigen selected from BCMA, GPC1, CD30, cMET, SAIL, HER3, CD70, CD46, CD48, HER2, 5T4, ENPP3, CD19, EGFR, and EphA2, or

wherein the first antibody binds an antigen selected from Her2, TROP2, BCMA, cMet, integrin alphVbeta6 (integrin αVβ6), CD22, CD79b, CD30, CD19, CD70, CD228, CD47, and CD48, or

wherein the first antibody binds an antigen selected from CD142, Integrin beta-6, integrin alphaVbeta6, ENPP3, CD19, Ly6E, cMET, C4.4a, CD37, MUC16, STEAP-1, LRRC15, SLITRK6, ETBR, FCRH5, Axl, EGFR, CD79b, BCMA, CD70, PSMA, CD79b, CD228, CD48, LIV-1, EphA2, SLC44A4, CD30, and sTn.

14. The use of any one of claims 1-13, wherein the first antibody does not bind Nectin-4, or
wherein the first medicament does not comprise an antibody-drug conjugate comprising an antibody that binds Nectin-4.

15. The use of any one of claims 1-14, wherein the tubulin disrupter is an auristatin, a tubulysin, a colchicine, a vinca alkaloid, a taxane, a cryptophycin, a maytansinoid, or a hemiasterlin, or
wherein the tubulin disrupter is an auristatin, or
wherein the tubulin disrupter is dolostatin-10, MMAE (N-methylvaline-valine-dolaisoleuine-dolaproine-norephedrine), MMAF (N-methylvaline-valine-dolaisoleuine-dolaproine-phenylalanine), auristatin F, AEB, AEVB, or AFP (auristatin phenylalanine phenylenediamine).

16. The use of any one of claims 1-15, wherein the tubulin disrupter is MMAE.

17. The use of claim 16, wherein the MMAE is conjugated to the first antibody through a linker that comprises valine and citrulline, or
wherein the MMAE is conjugated to the first antibody through a linker that comprises valine and citrulline, and the linker-MMAE is vcMMAE.

18. The use of claim 16, wherein the MMAE is conjugated to the first antibody through a linker that comprises leucine, alanine, and glutamic acid, or
wherein the MMAE is conjugated to the first antibody through a linker that comprises leucine, alanine, and glutamic acid, and the linker-MMAE is dLAE-MMAE.

19. The use of any one of claims 1-15, wherein the tubulin disrupter is MMAF.

20. The use of any one of claims 1-15, wherein the tubulin disrupter is a tubulysin, or wherein the tubulin disrupter is a tubulysin, and the tubulysin is selected from tubulysin D, tubulysin M, tubuphenylalanine, and tubutyrosine.

21. The use of any one of claims 1-15, wherein the antibody-drug conjugate is selected from AbGn-107 (Ab1-18Hr1), AGS62P1 (ASP1235), ALT-P7 (HM2-MMAE), BA3011 (CAB-AXL-ADC), belantamab mafodotin, brentuximab vedotin, cirmtuzumab vedotin (VLS-101, UC-961ADC3), cofetuzumab pelidotin (PF-06647020, PTK7-ADC, PF-7020, ABBV-647), CX-2029 (ABBV-2029), disitamab vedotin (RC48), enapotamab vedotin (HuMax-AXL-ADC, AXL-107-MMAE), enfortumab vedotin (EV), FS-1502 (LCB14-0110), gemtuzumab ozogamicin, HTI-1066 (SHR-A1403), inotuzumab ozogamicin, PF-06804103 (NG-HER2 ADC), polatuzumab vedotin, sacituzumab govitecan, SGN-B6A, SGN-CD228A , SGN-STNV, STI-6129 (CD38 ADC, LNDS1001, CD38-077 ADC), telisotuzumab vedotin (ABBV-399), tisotumab vedotin (Humax-TF-ADC, tf-011-mmae, TV), trastuzumab deruxtecan, trastuzumab emtansine, and vorsetuzumab mafodotin.

22. The use of any one of claims 1-21, wherein the first antibody is an anti-claudin-18.2 antibody that comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:61-66, or wherein the first antibody is an anti-claudin-18.2 antibody that comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:59 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:60, or
wherein the first antibody is an anti-claudin-18.2 antibody that is zolbetuximab (175D10), or
wherein the first antibody is an anti-claudin-18.2 antibody that comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 69-74, or
wherein the first antibody is an anti-claudin-18.2 antibody that comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:67 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:68, or
wherein the first antibody is an anti-PD-L1 antibody that comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:77-82, or

wherein the first antibody is an anti-PD-L1 antibody that comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:75 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:76, or

wherein the first antibody is an anti-ALP antibody that comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:85-90, or

wherein the first antibody is an anti-ALP antibody that comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:83 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:84, or

wherein the first antibody comprises an anti-B7H4 antibody that comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:93-98, or

wherein the first antibody comprises an anti-B7H4 antibody that comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:91 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:92, or

wherein the first antibody is an anti-HER2 antibody that comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:99 and a light chain comprising the amino acid sequence of SEQ ID NO:100, or

wherein the antibody-drug conjugate is disitamab vedotin, or

wherein the first antibody is an anti-NaPi2B antibody that comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:101 and a light chain comprising the amino acid sequence of SEQ ID NO:102, or

wherein the antibody-drug conjugate is lifastuzumab vedotin, or

wherein the first antibody is an anti-nectin-4 antibody that comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:105-110, or

wherein the first antibody is an anti-nectin-4 antibody that comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:103 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:104, or

wherein the antibody-drug conjugate is enfortumab vedotin, or

wherein the first antibody is an anti-AVB6 antibody that comprises a heavy chain CDR1, CDR2,

and CDR3, and a light chain CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:113-118, or

wherein the first antibody is an anti-AVB6 antibody that comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:37 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:38, or

wherein the first antibody is an anti-AVB6 antibody that comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:121-126, or

wherein the first antibody is an anti-AVB6 antibody that comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:119 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:120, or

wherein the first antibody is an anti-CD228 antibody that comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:129-134, or

wherein the first antibody is an anti-CD228 antibody that comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:127 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:128, or

wherein the first antibody is an anti-LIV-1 antibody that comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:137-142, or

wherein the first antibody is an anti-LIV-1 antibody that comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:135 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:136, or

wherein the first antibody is an anti-tissue factor antibody that comprises heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:145-150, or

wherein the first antibody is an anti-tissue factor antibody that comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:143 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:144, or

wherein the antibody-drug conjugate is tisotumab vedotin.

23. The use of any one of claims 1-22, wherein the second antibody binds an immune cell engager selected from anti-Mullerian Hormone Receptor II (AMHR2), B7, B7H1, B7H2, B7H3, B7H4, BAFF-R, BCMA (B-cell maturation antigen), Bst1/CD157, C5 complement, CC chemokine receptor 4 (CCR4), CD123, CD137, CD19, CD20, CD25 (IL2RA), CD276, CD278, CD3, CD32, CD33, CD37, CD38, CD4 and HIV-1 gp120-binding sites, CD40, CD70, CD70 (a member of the TNF receptor ligand family), CD80, CD86, Claudin 18.2, c-MET, CSF1R, CTLA-4, EGFR, EGFR MET proto-oncogene, EPHA3, ERBB2, ERBB3, FGFR2b, FLT3, GITR, glucocorticoid-induced TNF receptor (GITR), HER2, HER3, HLA, ICOS, IDO1, IFNAR1, IFNAR2, IGF-1R, IL-3Ralpha (CD123), IL-5R, IL-5Ralpha, LAG-3, MET proto-oncogene , OX40 (CD134), PD-1, PD-L1, PD-L2, PVRIG, respiratory syncytial virus (RSV) heavily glycosylated mucin-like domain of EBOV glycoprotein (GP), Rhesus (Rh) D, sialic acid immunoglobulin-like lectins 8 (Siglec-8), signaling lymphocyte activation molecule (SLAMF7/CS1), T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), TIGIT, TIM3 (HAVCR2), tumor specific glycoepitope of Muc1 (TA-Muc1), VSIR (VISTA), and VTCN1.

24. The use of any one of claims 1-23, wherein the second antibody binds TIGIT.

25. The use of claim 24, wherein the second antibody comprises:

(a) a heavy chain CDR1 comprising an amino acid sequence selected from SEQ ID NOs: 7-9;

(b) a heavy chain CDR2 comprising an amino acid sequence selected from SEQ ID NOs: 10-13;

(c) a heavy chain CDR3 comprising an amino acid sequence selected from SEQ ID NOs: 14-16;

(d) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 17;

(e) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 18; and

(f) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 19.

26. The use of claim 24, wherein the second antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR, and CDR3 comprising the sequences of:

(g) SEQ ID NOs: 7, 10, 14, 17, 18, and 19, respectively; or

(h) SEQ ID NOs: 8, 11, 14, 17, 18, and 19, respectively; or

(i) SEQ ID NOs: 9, 12, 15, 17, 18, and 19, respectively; or

(j) SEQ ID NOs: 8, 13, 16, 17, 18, and 19, respectively; or

(k) SEQ ID NOs: 8, 12, 16, 17, 18, and 19, respectively.

27. The use of claim 24, wherein the second antibody comprises a heavy chain variable region comprising an amino acid sequence selected from SEQ ID NOs: 1-5 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6.

28. The use of claim 24, wherein the second antibody comprises a heavy chain comprising an amino acid sequence selected from SEQ ID NOs: 20-24 and a light chain comprising the amino acid sequence of SEQ ID NO: 25.

29. The use of any one of claims 1-23, wherein the second antibody binds CD40, or wherein the second antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR, and CDR3 comprising the sequences of: (a) SEQ ID NOs: 30, 31, 32, 33, 34, and 35, respectively; or (b) SEQ ID NOs: 30, 36, 32, 33, 34, and 35, respectively, or
wherein the second antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 28 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 29, or
wherein the second antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 26 and a light chain comprising the amino acid sequence of SEQ ID NO: 27, or
wherein the second antibody binds CD70, or
wherein the second antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR, and CDR3 comprising the sequences of SEQ ID NOs: 53-58, respectively, or
wherein the second antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 41 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 42, or
wherein the second antibody binds BCMA, or
wherein the second antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR, and CDR3 comprising the sequences of SEQ ID NOs: 47-52, respectively, or

wherein the second antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 45 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 46.

30. The use of any one of claims 1-29, wherein the second antibody is an IgG1 or IgG3 antibody.

31. The use of any one of claims 1-30, wherein the second antibody is comprised in a composition of antibodies, wherein at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the antibodies in the composition are nonfucosylated.

32. The use of claim 31, wherein each antibody in the composition comprises the same heavy chain and light chain amino acid sequences as the second antibody.

33. The use of any one of claims 1-32, wherein the Fc of the second antibody has enhanced binding to one or more activating FcγRs as compared to a corresponding wild-type Fc of the same isotype, wherein the activating FcγRs include one or more of FcγRIIIa, FcγRIIa, and/or FcγRI, or
wherein the Fc of the second antibody has enhanced binding to FcγRIIIa.

34. The use of any one of claims 1-33, wherein the Fc of the second antibody has reduced binding to one or more inhibitory FcγRs as compared to a corresponding wild-type Fc of the same isotype, or
wherein the Fc of the second antibody has reduced binding to FcγRIIb, or
wherein the Fc of the second antibody has enhanced binding to FcγRIIIa and reduced binding to FcγRIIb.

35. The use of any one of claims 1-34, wherein the second antibody is a monoclonal antibody.

36. The use of any one of claims 1-35, wherein the second antibody is a humanized antibody or a human antibody.

37. The use of any one of claims 1-36, wherein the cancer is bladder cancer, breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, colorectal cancer, colon cancer, kidney cancer, clear cell renal carcinoma, head and neck cancer, lung cancer, lung adenocarcinoma, stomach cancer, germ cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, melanoma, neoplasm of the central nervous system, mesothelioma, lymphoma, leukemia, chronic lymphocytic leukemia, diffuse large B cell lymphoma, follicular lymphoma, Hodgkin lymphoma, myeloma, or sarcoma, or
wherein the cancer is lymphoma, leukemia, chronic lymphocytic leukemia, diffuse large B cell lymphoma, follicular lymphoma, or Hodgkin lymphoma.

38. The use of any one of claims 1-37, wherein the antibody-drug conjugate and the second antibody are to be administered concurrently, or
wherein the antibody-drug conjugate and the second antibody are to be administered in a single pharmaceutical composition.

39. The use of any one of claims 1-37, wherein the antibody-drug conjugate and the second antibody are to be administered sequentially, or
wherein at least a first dose of the antibody-drug conjugate is to be administered prior to a first dose of the second antibody; or wherein at least a first dose of the second antibody is to be administered prior to a first dose of the antibody-drug conjugate.

40. The use of any one of claims 1-39, wherein the second antibody depletes T regulatory cells (Tregs).

41. The use of any one of claims 1-40, wherein the antibody-drug conjugate induces immune memory against cells expressing the antigen bound by the antibody-drug conjugate, or
wherein the antibody-drug conjugate induces immune memory against cells expressing the antigen bound by the antibody-drug conjugate, and the induction of immune memory comprises induction of memory T cells, or
wherein the second antibody activates antigen presenting cells (APCs), or
wherein the second antibody enhances CD8 T cell responses, or
wherein the second antibody upregulates co-stimulatory receptors, or

wherein administration of the ADC and the second antibody promotes release of an immune activating cytokine, or
wherein administration of the ADC and the second antibody promotes release of an immune activating cytokine, and the immune activating cytokine is CXCL10 or IFNγ, or
wherein the ADC and the second antibody act synergistically, or
wherein administration of the ADC and the second antibody in combination has a toxicity profile comparable to that of the ADC or the second antibody when either is administered as monotherapy, or
wherein the effective dose of the ADC and/or the second antibody when dosed in combination is less than when administered as monotherapy.

42. The use of any one of claims 1-41, wherein the cancer has high tumor mutation burden, or
wherein the cancer has microsatellite instability.